Drug Description in Trials / DrugBank / KEGG DRUG /

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
12-[[[(2R)-1-[1-[(4-CHLORO-3-METHYLPHENYL)METHYL]-4- PIPERIDINYL]-5-OXO-2-PYRROLIDINYL]CARBONYL]AMINO]- N,N,6-TRIMETHYL-4-PYRIDINECARBOXAMIDE,DIHYDROCHLORIDE----2件: 6, 162 💬
2A single blood sample for HLA typing----3件: 35, 38, 162 💬
3AC-203 1% Topical Ointment----1件: 162 💬
4AKST4290----2件: 6, 162 💬
5ALLOGENEIC ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS EXPANDED----5件: 36, 38, 53, 96, 162 💬
6Allogenic mesenchymal stem cell isolated from adipose tissue----3件: 38, 96, 162 💬
7Apremilast1件: Apremilast1件: Apremilast 💬4件: PDE4A,
PDE4B,
PDE4C,
PDE4D 💬		5件: Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway 💬7件: 46, 50, 56, 97, 107, 162, 271 💬
8ARAVA1件: Leflunomide1件: Leflunomide 💬1件: DHODH 💬3件: Biosynthesis of cofactors, Metabolic pathways, Pyrimidine metabolism 💬3件: 46, 53, 162 💬
9Avdoralimab1件: Avdoralimab---1件: 162 💬
10Avdoralimab (IPH5401)1件: Avdoralimab---1件: 162 💬
11Azathioprine1件: Azathioprine1件: Azathioprine 💬--21件: 6, 11, 13, 19, 35, 42, 43, 44, 45, 46, 49, 63, 65, 66, 85, 93, 94, 95, 96, 97, 162 💬
12Azathioprine or Mycophenolate mofetil3件: Azathioprine,
Mycophenolate mofetil,
Mycophenolic acid		3件: Azathioprine ,
Mycophenolate mofetil ,
Mycophenolic acid 💬		2件: IMPDH1,
IMPDH2 💬		4件: Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬1件: 162 💬
13Baricitinib1件: Baricitinib1件: Baricitinib 💬2件: JAK1,
JAK2 💬		35件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬13件: 2, 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
14Baricitinib 2 MG [Olumiant]1件: Baricitinib1件: Baricitinib 💬2件: JAK1,
JAK2 💬		35件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬1件: 162 💬
15Benralizumab1件: Benralizumab1件: Benralizumab 💬1件: IL5RA 💬4件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬5件: 44, 45, 98, 162, 299 💬
16Bertilimumab----2件: 97, 162 💬
17BIV009----2件: 61, 162 💬
18Blood test----6件: 36, 51, 107, 113, 162, 299 💬
19CC----13件: 28, 46, 49, 51, 56, 84, 85, 96, 97, 98, 162, 202, 271 💬
20CC-10004----5件: 46, 56, 97, 162, 271 💬
21Cellcept® in autoimmune bullous dermatoses----2件: 35, 162 💬
22Clobetasol1件: Clobetasol1件: Clobetasol 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬4件: 39, 46, 51, 162 💬
23Clobetasol 0.05% Topical Ointment1件: Clobetasol1件: Clobetasol 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 162 💬
24Clobetasol Propionate2件: Clobetasol,
Clobetasol propionate		2件: Clobetasol propionate ,
Clobetasol 💬		1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬2件: 46, 162 💬
25Clobetasol propionate + Methotrexate3件: Clobetasol,
Clobetasol propionate,
Methotrexate		3件: Methotrexate ,
Clobetasol propionate ,
Clobetasol 💬		3件: DHFR,
DHFR2,
NR3C1 💬		6件: Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, Neuroactive ligand-receptor interaction, One carbon pool by folate 💬1件: 162 💬
26Clobetasol propionate alone2件: Clobetasol,
Clobetasol propionate		2件: Clobetasol propionate ,
Clobetasol 💬		1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 162 💬
27Clobetasol Propionate cream treatment2件: Clobetasol,
Clobetasol propionate		2件: Clobetasol propionate ,
Clobetasol 💬		1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 162 💬
28Cortancyl1件: Prednisone acetate1件: Prednisone acetate 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬3件: 35, 41, 162 💬
29CORTANCYL 20 mg1件: Prednisone acetate1件: Prednisone acetate 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬2件: 35, 162 💬
30Cultivated oral mucosal epithelial sheet transplantation----2件: 38, 162 💬
31Cyclophosphamide1件: Cyclophosphamide2件: Cyclophosphamide ,
Cyclophosphamide 💬		--44件: 11, 13, 14, 16, 19, 20, 26, 28, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 56, 60, 62, 65, 66, 84, 85, 93, 96, 162, 164, 172, 205, 222, 224, 256, 274, 283, 284, 285, 288, 326, 331 💬
32Cyclophosphamide 50Mg Oral Tablet1件: Cyclophosphamide2件: Cyclophosphamide ,
Cyclophosphamide 💬		--1件: 162 💬
33Cyclosporine1件: Cyclosporine1件: Cyclosporine 💬5件: PPP3CA,
PPP3CB,
PPP3CC,
PPP3R1,
PPP3R2 💬		33件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬37件: 11, 19, 20, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 107, 162, 164, 222, 226, 228, 234, 283, 284, 285, 302 💬
34Dapsone1件: Dapsone1件: Dapsone 💬--5件: 35, 42, 60, 84, 162 💬
35Data report----1件: 162 💬
36Dermoval----2件: 35, 162 💬
37Dexamethasone1件: Dexamethasone1件: Dexamethasone 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬22件: 13, 14, 16, 28, 35, 46, 53, 63, 64, 65, 70, 81, 84, 96, 97, 162, 222, 235, 257, 283, 296, 299 💬
38Dexamethasone 0.5mg/5ml solution1件: Dexamethasone1件: Dexamethasone 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬2件: 35, 162 💬
39Dexamethasone 0.5mg/5ml solution in Mucolox™1件: Dexamethasone1件: Dexamethasone 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬2件: 35, 162 💬
40DF2156A----1件: 162 💬
41Double Dose----2件: 38, 162 💬
42Doxycycline1件: Doxycycline2件: Doxycycline ,
Doxycycline 💬		--17件: 13, 23, 28, 34, 46, 84, 85, 89, 96, 97, 158, 161, 162, 167, 227, 280, 299 💬
43Dupilumab1件: Dupilumab1件: Dupilumab 💬1件: IL4R 💬8件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬5件: 51, 97, 98, 160, 162 💬
44Dupixent1件: Dupilumab1件: Dupilumab 💬1件: IL4R 💬8件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬3件: 98, 160, 162 💬
45EFGARTIGIMOD ALFA1件: Efgartigimod alfa1件: Efgartigimod alfa 💬1件: FCGRT 💬-6件: 11, 14, 35, 53, 63, 162 💬
46Efgartigimod PH20 SC----5件: 11, 14, 35, 63, 162 💬
47Fasenra1件: Benralizumab1件: Benralizumab 💬1件: IL5RA 💬4件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬5件: 44, 45, 98, 162, 299 💬
48Gold1件: Gold---43件: 2, 5, 6, 13, 17, 34, 35, 46, 49, 50, 53, 58, 63, 65, 68, 76, 84, 86, 91, 93, 95, 96, 97, 98, 113, 137, 158, 162, 167, 171, 193, 218, 222, 224, 226, 227, 230, 271, 291, 296, 298, 310, 318 💬
49Halometasone1件: Halometasone1件: Halometasone 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 162 💬
50Imatinib1件: Imatinib1件: Imatinib 💬3件: ABL1,
KIT,
PDGFRA 💬		32件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
51Infliximab1件: Infliximab1件: Infliximab 💬1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬26件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
52INTERLEUKIN-21件: Human interleukin-2---10件: 2, 35, 49, 50, 53, 55, 65, 96, 97, 162 💬
53IPH5401----1件: 162 💬
54Ixekizumab1件: Ixekizumab1件: Ixekizumab 💬1件: IL17A 💬6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬8件: 36, 37, 46, 107, 160, 162, 269, 271 💬
55Ladarixin1件: Ladarixin---1件: 162 💬
56Large dose of prednisolone plus intra-lesional of Triamcinolone Acetonide followed the systemic combination of mycophenolate mofetil (MMF), dapsone and low dose prednisolone in treatment of MMP5件: Dapsone,
Mycophenolate mofetil,
Mycophenolic acid,
Prednisolone,
Triamcinolone		5件: Triamcinolone ,
Prednisolone ,
Dapsone ,
Mycophenolate mofetil ,
Mycophenolic acid 💬		3件: IMPDH1,
IMPDH2,
NR3C1 💬		5件: Drug metabolism - other enzymes, Metabolic pathways, Neuroactive ligand-receptor interaction, Nucleotide metabolism, Purine metabolism 💬1件: 162 💬
57Leflunomide1件: Leflunomide1件: Leflunomide 💬1件: DHODH 💬3件: Biosynthesis of cofactors, Metabolic pathways, Pyrimidine metabolism 💬12件: 11, 40, 46, 49, 53, 66, 107, 162, 224, 270, 271, 300 💬
58MabThera1件: Rituximab1件: Rituximab 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬22件: 11, 13, 14, 19, 35, 43, 44, 46, 49, 50, 51, 52, 53, 61, 63, 64, 65, 83, 93, 162, 222, 271 💬
59Mabthéra----2件: 35, 162 💬
60Mathéra----2件: 35, 162 💬
61MEDI-563----5件: 44, 45, 98, 162, 299 💬
62Medrone----4件: 46, 51, 83, 162 💬
63MEPOLIZUMAB1件: Mepolizumab1件: Mepolizumab 💬1件: IL5 💬13件: Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬4件: 44, 45, 98, 162 💬
64Mepolizumab (a-IL-5 antibody)1件: Mepolizumab1件: Mepolizumab 💬1件: IL5 💬13件: Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬1件: 162 💬
65Methotrexate1件: Methotrexate1件: Methotrexate 💬2件: DHFR,
DHFR2 💬		5件: Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 💬
66Methylprednisolone1件: Methylprednisolone1件: Methylprednisolone 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬46件: 2, 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 85, 86, 93, 95, 96, 97, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296 💬
67Minocycline1件: Minocycline1件: Minocycline 💬--13件: 2, 6, 8, 13, 46, 85, 90, 94, 162, 201, 206, 280, 299 💬
68MMF----16件: 13, 35, 40, 46, 49, 50, 51, 60, 65, 66, 107, 162, 222, 224, 226, 299 💬
69Mometasone2件: Mometasone,
Mometasone furoate		2件: Mometasone furoate ,
Mometasone 💬		1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬2件: 98, 162 💬
70MOMETASONE FUROATE2件: Mometasone,
Mometasone furoate		2件: Mometasone furoate ,
Mometasone 💬		1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬2件: 98, 162 💬
71MTX----14件: 13, 35, 40, 46, 49, 50, 51, 60, 84, 96, 97, 107, 162, 271 💬
72Mycophenolate1件: Mycophenolic acid1件: Mycophenolic acid 💬2件: IMPDH1,
IMPDH2 💬		4件: Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬36件: 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 84, 85, 93, 95, 96, 162, 164, 222, 224, 226, 228, 234, 283, 284, 285, 300 💬
73Mycophenolate mofetil2件: Mycophenolate mofetil,
Mycophenolic acid		2件: Mycophenolate mofetil ,
Mycophenolic acid 💬		2件: IMPDH1,
IMPDH2 💬		4件: Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬34件: 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 💬
74Myfortic1件: Mycophenolic acid1件: Mycophenolic acid 💬2件: IMPDH1,
IMPDH2 💬		4件: Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬5件: 49, 66, 162, 222, 228 💬
75Myfortic 180 mg1件: Mycophenolic acid1件: Mycophenolic acid 💬2件: IMPDH1,
IMPDH2 💬		4件: Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬1件: 162 💬
76Myfortic 180 mg Filmtabletten1件: Mycophenolic acid1件: Mycophenolic acid 💬2件: IMPDH1,
IMPDH2 💬		4件: Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬1件: 162 💬
77Nicotinamide1件: Nicotinamide1件: Niacinamide 💬--8件: 2, 6, 18, 49, 97, 107, 162, 191 💬
78NNC0215-0384----2件: 46, 162 💬
79NOMACOPAN1件: Nomacopan1件: Nomacopan 💬1件: C5 💬11件: Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬1件: 162 💬
80Nomacopan (rVA576)1件: Nomacopan1件: Nomacopan 💬1件: C5 💬11件: Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬1件: 162 💬
81NPB-01----3件: 13, 14, 162 💬
82Olive1件: Olea europaea leaf---5件: 13, 35, 49, 53, 162 💬
83Olive oil2件: Olea europaea leaf,
Olive oil		1件: Olive oil 💬--5件: 13, 35, 49, 53, 162 💬
84OMALIZUMAB1件: Omalizumab1件: Omalizumab 💬1件: FCER1A 💬4件: Asthma, Fc epsilon RI signaling pathway, Phospholipase D signaling pathway, Sphingolipid signaling pathway 💬7件: 46, 53, 65, 98, 162, 226, 299 💬
85Oral corticosteroids (OCS)----1件: 162 💬
86Otezla1件: Apremilast1件: Apremilast 💬4件: PDE4A,
PDE4B,
PDE4C,
PDE4D 💬		5件: Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway 💬3件: 56, 107, 162 💬
87Ozonated olive oil2件: Olea europaea leaf,
Olive oil		1件: Olive oil 💬--2件: 35, 162 💬
88PREDNISOLONE1件: Prednisolone1件: Prednisolone 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬42件: 3, 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300 💬
89Prednisone1件: Prednisone1件: Prednisone 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬45件: 2, 11, 13, 14, 19, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 79, 81, 84, 85, 86, 95, 96, 97, 113, 162, 164, 205, 222, 224, 228, 283, 284, 288, 299, 300, 307, 331 💬
90QGE031----1件: 162 💬
91Restasis1件: Cyclosporine1件: Cyclosporine 💬5件: PPP3CA,
PPP3CB,
PPP3CC,
PPP3R1,
PPP3R2 💬		33件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬2件: 53, 162 💬
92Riboflavin1件: Riboflavin1件: Riboflavin 💬--7件: 38, 46, 96, 97, 162, 168, 265 💬
93RITUXIMAB1件: Rituximab1件: Rituximab 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬48件: 11, 13, 14, 19, 26, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 53, 55, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 162, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331 💬
94Rituximab 1g IV1件: Rituximab1件: Rituximab 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 162 💬
95Rituximab combined with Omalizumab2件: Omalizumab,
Rituximab		2件: Rituximab ,
Omalizumab 💬		2件: FCER1A,
MS4A1 💬		5件: Asthma, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, Phospholipase D signaling pathway, Sphingolipid signaling pathway 💬1件: 162 💬
96RVA576----3件: 62, 109, 162 💬
97Simvastatin1件: Simvastatin1件: Simvastatin 💬1件: HMGCR 💬4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬21件: 6, 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 160, 162, 195, 265, 288, 298, 299, 310 💬
98Simvastatin-ratiopharm1件: Simvastatin1件: Simvastatin 💬1件: HMGCR 💬4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬1件: 162 💬
99Simvastatin-ratiopharm®1件: Simvastatin1件: Simvastatin 💬1件: HMGCR 💬4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬1件: 162 💬
100Single Dose----2件: 38, 162 💬
101Solu-Medrone----3件: 51, 83, 162 💬
102Tildrakizumab1件: Tildrakizumab1件: Tildrakizumab 💬1件: IL23A 💬9件: C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬2件: 162, 271 💬
103Tildrakizumab Prefilled Syringe1件: Tildrakizumab1件: Tildrakizumab 💬1件: IL23A 💬9件: C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬1件: 162 💬
104Topical garamycin cream----2件: 35, 162 💬
105Topical infliximab1件: Infliximab1件: Infliximab 💬1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬3件: 38, 39, 162 💬
106Treatment systemic therapy (prednisone)1件: Prednisone1件: Prednisone 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 162 💬
107Treatment with systemic therapy (doxycycline)1件: Doxycycline2件: Doxycycline ,
Doxycycline 💬		--1件: 162 💬
108Treatment with systemic therapy (methotrexate)1件: Methotrexate1件: Methotrexate 💬2件: DHFR,
DHFR2 💬		5件: Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬1件: 162 💬
109Treatment with systemic therapy (prednisone)1件: Prednisone1件: Prednisone 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 162 💬
110Treatment with topical superpotent corticosteroid therapy----1件: 162 💬
111Triamcinolone1件: Triamcinolone1件: Triamcinolone 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬11件: 35, 46, 53, 56, 70, 90, 96, 107, 162, 226, 298 💬
112Tripterygium1件: Tripterygium wilfordii whole---8件: 46, 66, 67, 96, 162, 222, 224, 271 💬
113Ustekinumab1件: Ustekinumab1件: Ustekinumab 💬3件: IL12A,
IL12B,
IL23A 💬		28件: African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬